This article is more than 5 years old. Information may no longer be current.

Teva launches generic olopatadine solution

Issue: July 2017

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Teva Pharmaceutical Ind. has launched a generic version of Pataday, the company announced in a press release.

Olopatadine HCl ophthalmic solution 0.2%, marketed by Alcon as Pataday, is a mast-cell stabilizer used to treat ocular itching associated with allergic conjunctivitis.

“Olopatadine HCl ophthalmic solution 0.2% is an important treatment for our patients and a key addition to our generics product portfolio,” Dipankar Bhattacharjee, president and CEO of global generic medicines at Teva, said in the release. “This launch marks another successful first-to-file product for Teva, bringing the only generic version of this product on the market.”